Optimal treatment of complicated skin and skin structure infections.
about
Toward New Therapeutics for Skin and Soft Tissue Infections: Propargyl-Linked Antifolates Are Potent Inhibitors of MRSA and Streptococcus pyogenesEpidemiology and Outcomes of Complicated Skin and Soft Tissue Infections among Inpatients in Southern China from 2008 to 2013Kinetic analysis and modeling of daptomycin batch fermentation by Streptomyces roseosporus.Photodynamic effects of novel XF porphyrin derivatives on prokaryotic and eukaryotic cells.Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections.Randomized comparison of linezolid (PNU-100766) versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infections.Antibiotic optimization in the difficult-to-treat patient with complicated intra-abdominal or complicated skin and skin structure infections: focus on tigecycline.Resistance and the management of complicated skin and skin structure infections: the role of ceftobiprole.The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections.A prospective, multicenter, observational study of complicated skin and soft tissue infections in hospitalized patients: clinical characteristics, medical treatment, and outcomes.A randomized trial of the efficacy and safety of sequential intravenous/oral moxifloxacin monotherapy versus intravenous piperacillin/tazobactam followed by oral amoxicillin/clavulanate for complicated skin and skin structure infectionsExposure-response analyses of tigecycline efficacy in patients with complicated skin and skin-structure infections.Meropenem in the treatment of complicated skin and soft tissue infectionsRole of linezolid in the treatment of complicated skin and soft tissue infections.Tigecycline in the treatment of complicated intra-abdominal and complicated skin and skin structure infections.Skin and skin structure infections: treatment with newer generation fluoroquinolones.The efficacy and safety of arbekacin and vancomycin for the treatment in skin and soft tissue MRSA infection: preliminary studyMulticenter, randomized study of the efficacy and safety of intravenous iclaprim in complicated skin and skin structure infectionsAntistaphylococcal activity of CB-181963 (CAB-175), an experimental parenteral cephalosporin.Ceftobiprole: a new cephalosporin for the treatment of skin and skin structure infections.Sequential intravenous/oral moxifloxacin monotherapy for complicated skin and skin structure infections: a meta-analysis of randomised controlled trials.Antipneumococcal and antistaphylococcal activities of ranbezolid (RBX 7644), a new oxazolidinone, compared to those of other agents.Antistaphylococcal activity of LBM415, a new peptide deformylase inhibitor, compared with those of other agents.Antistaphylococcal activity of dalbavancin, an experimental glycopeptide.Antistaphylococcal activity of DX-619, a new des-F(6)-quinolone, compared to those of other agents.Antistaphylococcal activity of DX-619 alone and in combination with vancomycin, teicoplanin, and linezolid assessed by time-kill synergy testingErtapenem once daily versus piperacillin-tazobactam 4 times per day for treatment of complicated skin and skin-structure infections in adults: results of a prospective, randomized, double-blind multicenter study.
P2860
Q27677355-8DF3D736-63B8-4C99-ABDF-51FE38A05463Q28550407-EE1E61A7-82BD-4745-9192-8F89F2F87A9DQ33681139-B85569B0-59C1-4F90-8020-9958F21E83ABQ33722039-437D91F4-7698-4990-95C6-6F079399BF85Q33836490-81FF76A0-4FDE-45CB-9110-5B91C94ECB6BQ33981016-0A9FC729-3E0E-4684-887A-DD7EE51177FDQ34133346-707A1433-A367-4AA4-8D15-7B54C87F8858Q34187667-963CC222-1BF2-4D97-AB70-3F7B3A11440CQ34330270-8B2D5907-25B7-4617-ABDD-32FFE86293C3Q34420942-BC73A43A-6F97-4A55-9618-A0B9C10B9755Q35328383-B1CBF666-50E0-416F-BC03-06A15C73D11BQ35840772-F6971755-F7EC-49A7-9912-B60BBEE737A8Q35919254-3222B0A5-690A-4734-B6CC-332251D83A76Q36505478-3707C5E9-D53E-460B-8D9A-3FF4DD26D81AQ36663656-D34947E0-7FAC-4D40-933B-6D8A676D9918Q37116838-79F835B6-77C0-45CD-B2A0-A03750F7EA57Q37192126-ADF96E3F-2BB4-4C42-B9D3-D04BBE703113Q37247772-CDDA53F5-0486-43C6-B651-E16F2EB61F48Q37568895-51FD7B6D-D5E4-49C9-ADFC-58AFCDEB30A5Q37593094-4B248BEA-F1D8-4927-B8ED-68468D0776FDQ38129444-0234F94D-7E7A-4B56-B94F-B477067987E0Q39732005-0498C1F6-0E19-4AA9-A90B-36A3EDF738EBQ40165422-92302C6E-3F41-44BB-A3C9-C622F573E288Q41005410-2417F5EF-EE81-4802-9E79-19ED46B52880Q41816467-7A13EDDA-4F63-466C-B40A-D186933B13EAQ42070285-4A3D812C-0328-46EB-8B5A-E519B2148549Q43996920-777C3927-F392-4863-993A-C1F665994890
P2860
Optimal treatment of complicated skin and skin structure infections.
description
1999 nî lūn-bûn
@nan
1999 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Optimal treatment of complicated skin and skin structure infections.
@ast
Optimal treatment of complicated skin and skin structure infections.
@en
type
label
Optimal treatment of complicated skin and skin structure infections.
@ast
Optimal treatment of complicated skin and skin structure infections.
@en
prefLabel
Optimal treatment of complicated skin and skin structure infections.
@ast
Optimal treatment of complicated skin and skin structure infections.
@en
P356
P1476
Optimal treatment of complicated skin and skin structure infections.
@en
P2093
Nichols RL
P356
10.1093/JAC/44.SUPPL_1.19
P407
P478
44 Suppl A
P577
1999-09-01T00:00:00Z